Tuesday, August 7, 2012


Progress in the treatment of multiple myeloma is slow (let us not speak of "cures" here). Over the past couple of decades, the options developed, aside from the nuclear one (bone marrow or stem cell transplant), are the three FDA-approved agents thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade). These, and various cocktails combining them with each other, with steroids, etc., comprise the universe of weapons commonly used against this cancer.

A few weeks ago, a fourth contestant entered the lists: carfilzomib, called by the brand name Kyprolis by its manufacturer, Onyx Pharmaceuticals, received FDA approval for the treatment of multiple myeloma. As usual, formal approval is for an absurdly narrow scenario, namely for patients who have developed resistance to two of the other therapies and who showed progression within 60 days of completing the last therapy. The clinical trial on which the approval was based involved just 266 such patients. On such slender scientific threads do our fates turn. Of course, the restrictions imposed by the approval are a polite fiction; having received approval for some usage, carfilzomib can now in reality be used by oncologists for any use that seems to them likely to provide some benefit, as indicated by further research. Fortunately.


  1. I am one of those few newly diagnosed who is getting carfilzomib. I am in the special NIH CRD trial and my disease has been reduced by 99% in three months. Will it last??? I hope so!

    1. Best of luck. I'm curious; is this being presented to you as induction therapy leading to a stem cell transplant, or as something that is hoped to be sufficiently effective to remove the need for a transplant? Would you be eligible for a transplant, if it came to that?

  2. Hi,

    I have a quick question about your blog, would you mind emailing me when you get a chance?




  3. Homeopathy and varicose veins
    or varicositiesThe homeopathic remedies or treatment work at relieving stagnation of blood and help in its recirculation by improving the elasticity of the veins walls.

    Bone marrow transplant surgery
    in India costs very low when compared with US and Europe. This is because the infrastructure costs are lower than in UK and Europe. It is said that the low cost makes the quality worst but it is totally wrong with India. India is giving world class treatment to the international patients and it is reflected by the increased number of surgeries here.

    Varicose Veins surgery in india

    Bone marrow transplant cost in India

    Minimally invasive surgery India

    Cataract implant surgery India